You are not logged in.

Pharmaceutical ecomonics and politics vs. patient safety : Lumiracoxib in Australia

Whitstock, Margaret T., Eckermann, Elizabeth J., Majoribanks, Tomothy K. and Pearce, Christopher M. 2008, Pharmaceutical ecomonics and politics vs. patient safety : Lumiracoxib in Australia, The international journal of risk and safety in medicine, vol. 20, no. 3, pp. 161-167.

Attached Files
Name Description MIMEType Size Downloads

Title Pharmaceutical ecomonics and politics vs. patient safety : Lumiracoxib in Australia
Author(s) Whitstock, Margaret T.
Eckermann, Elizabeth J.ORCID iD for Eckermann, Elizabeth J. orcid.org/0000-0002-4908-5629
Majoribanks, Tomothy K.
Pearce, Christopher M.
Journal name The international journal of risk and safety in medicine
Volume number 20
Issue number 3
Start page 161
End page 167
Total pages 7
Publisher Elsevier
Place of publication Amsterdam, The Netherlands
Publication date 2008
ISSN 0924-6479
1878-6847
Keyword(s) COX-2 inhibitors
coxibs
lumiracoxib
NSAIDs
pharmaceutical regulatory policy (Australia)
prexige
Summary Lumiracoxib (Prexige©) 200 mg was listed in Australia’s Pharmaceutical Benefits Scheme (PBS) schedules on 01 August 2006. The listing was intended as a cost-minimisation strategy, as lumiracoxib 200 mg was deemed equivalent in therapeutic effect to celecoxib (Celebrex©) 200 mg, and was available at a lower cost. By the time of listing on the PBS, a safety re-evaluation of the recommended daily dose of lumiracoxib was being considered in other national regulatory jurisdictions. Within 3 months of listing, the manufacturer revised the recommended dosage to half that of the PBS-listed dosage. However, the PBS listing was neither revoked nor modified. At the time of listing on the PBS, lumiracoxib was known to be 17 times as biochemically selective in inhibiting the COX-2 isoform as celecoxib, and twice as selective as rofecoxib, already withdrawn for safety reasons. Safety concerns had already been raised about adverse hepatic outcomes on daily doses of lumiracoxib 200 mg. Communication of information about the risk potential of lumiracoxib was inadequate. Economic and political considerations were prioritised over patient safety, and lumiracoxib 200 mg remained available via the PBS until 10 August 2007, when it was withdrawn for safety reasons following cases of hepatic morbidity and mortality.
Language eng
Field of Research 111799 Public Health and Health Services not elsewhere classified
Socio Economic Objective 929999 Health not elsewhere classified
HERDC Research category C1 Refereed article in a scholarly journal
HERDC collection year 2008
Copyright notice ©2008, IOS Press and the authors
Persistent URL http://hdl.handle.net/10536/DRO/DU:30017946

Document type: Journal Article
Collection: School of History, Heritage and Society
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 735 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Fri, 14 Aug 2009, 13:58:59 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.